Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Historic Proforma Category Financial Performance

7th Jul 2025 07:00

RNS Number : 9602P
Haleon PLC
07 July 2025
 

 

 

 

Haleon plc: Historic Proforma Category Financial Performance

7 July 2025: Haleon plc (the "Company" or "Haleon") today releases the historical proforma category financial information, aligned with the announcement at the Capital Markets Day on 1 May 2025. Haleon will now be reporting six categories: Oral Health; Vitamins, Minerals, and Supplements (VMS); Pain Relief; Respiratory Health; Digestive Health; and Therapeutic Skin Health and Other.

Compared to previous reporting, the new structure:

Splits out Digestive Health & Other into Digestive Health, and Therapeutic Skin Health and Other

Smokers Health which had previously been reported as part of Digestive Health and Other will now be included in Respiratory Health

There are no changes to other categories not outlined above

 

We will begin reporting in this new category structure at our 2025 Half Year Results on 31 July 2025. The purpose of this change is to better align Haleon's reporting with the strategic opportunities ahead as well as improve visibility of Haleon's financial performance. Haleon's geographical split remains unchanged.

Detailed below is the quarterly pro-forma actual and comparative financial information on this basis. Definitions for non-IFRS measures can be found on pages 19-27 in Haleon's 2024 Full Year Results, and pages 43-50 in Haleon's Annual Report and Form 20-F 2024.

Restated FY 2023 and FY 2024 reported revenue, organic revenue growth, and reported revenue growth by category (unaudited)

2023

 

2024

 

£m revenue

Organic Revenue Growth

Reported Revenue Growth

 

£m revenue

Organic Revenue Growth

Reported Revenue Growth

Oral Health

3,136

10.6%

6.1%

3,312

9.6%

5.6%

VMS

1,640

0.9%

-2.1%

1,696

7.6%

3.4%

Pain Relief

2,652

7.4%

4.0%

2,564

0.1%

-3.3%

Respiratory Health

2,244

11.7%

8.2%

2,122

1.0%

-5.4%

Digestive Health

1,012

5.8%

1.9%

1,029

5.5%

1.7%

Therapeutic Skin Health and Other

618

8.8%

1.5%

510

9.8%

-17.5%

TOTAL

11,302

8.0%

4.1%

 

11,233

5.0%

-0.6%

 

Restated quarterly reported revenue by category (unaudited)

2023

 

2024

 

2025

£m

Q1

Q2

Q3

Q4

FY

 

Q1

Q2

Q3

Q4

FY

 

Q1

Oral Health

811

778

790

757

3,136

854

829

810

819

3,312

880

VMS

405

411

410

414

1,640

422

435

407

432

1,696

416

Pain Relief

724

681

636

611

2,652

662

641

628

633

2,564

661

Respiratory Health

638

455

563

588

2,244

590

454

581

497

2,122

525

Digestive Health

259

256

234

263

1,012

256

264

239

270

1,029

254

Therapeutic Skin Health and Other

149

171

165

133

618

135

152

115

108

510

117

TOTAL

 2,986

 2,752

 2,798

 2,766

 11,302

 

 2,919

 2,775

 2,780

 2,759

 11,233

 

 2,853

 

Restated quarterly organic revenue growth by category (unaudited)

 

2023

 

2024

 

2025

%

FY

 

Q1

Q2

Q3

Q4

FY

 

Q1

Oral Health

10.6%

10.6%

9.1%

8.2%

10.6%

9.6%

6.6%

VMS

0.9%

9.9%

8.5%

3.7%

8.2%

7.6%

0.9%

Pain Relief

7.4%

-4.8%

-4.0%

3.1%

7.4%

0.1%

2.6%

Respiratory Health

11.7%

-2.7%

1.3%

8.2%

-2.6%

1.0%

0.7%

Digestive Health

5.8%

2.2%

5.2%

9.0%

5.8%

5.5%

2.3%

Therapeutic Skin Health and Other

8.8%

7.4%

10.7%

0.7%

24.2%

9.8%

10.4%

TOTAL

8.0%

 

3.0%

4.1%

6.1%

6.8%

5.0%

 

3.5%

 

Restated quarterly reported revenue growth by category (unaudited)

 

2023

 

2024

 

2025

%

FY

 

Q1

Q2

Q3

Q4

FY

 

Q1

Oral Health

6.1%

5.3%

6.6%

2.5%

8.2%

5.6%

3.0%

VMS

-2.1% 

4.2%

5.8%

-0.7%

4.3%

3.4%

-1.4%

Pain Relief

4.0% 

-8.6%

-5.9%

-1.3%

3.6%

-3.3%

-0.2%

Respiratory Health

8.2% 

-7.5%

-0.2%

3.2%

-15.5%

-5.4%

-11.0%

Digestive Health

1.9% 

-1.2%

3.1%

2.1%

2.7%

1.7%

-0.8%

Therapeutic Skin Health and Other

1.5% 

-9.4%

-11.1%

-30.3%

-18.8%

-17.5%

-13.3%

TOTAL

4.1% 

 

-2.2%

0.8%

-0.6%

-0.3%

-0.6%

 

-2.3%

 

 

Enquiries

 

Investors

Media

 

Jo Russell

+44 7787 392441

Zoë Bird

+44 7736 746167

Rakesh Patel

+44 7552 484646

Victoria Durman

+44 7894 505730

Emma White

+44 7823 523562

 

Email: [email protected]

Email: [email protected]

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUPUGCMUPAPGQ

Related Shares:

Haleon
FTSE 100 Latest
Value8,813.14
Change6.61